论文部分内容阅读
治疗组 96例 ,采用益肾平哮口服液联合倍氯米松气雾剂治疗 ,对照组 92例采用倍氯米松气雾剂治疗。结果 :近期临床治愈率 ,治疗组 5 0 .0 % ,显著高于对照组的 2 0 .7% ( P<0 .0 1) ;近期总有效率 ,治疗组 97.9% ,显著高于对照组的 83.7% ( P<0 .0 5 )。远期临床治愈率 ,治疗组 79.2 % ,显著高于对照组的 2 5 .0 % ( P<0 .0 1) ;远期总有效率 ,治疗组99.0 % ,显著高于对照组的 79.3% ( P<0 .0 5 )。治疗组未见明显不良反应 ,而对照组口腔霉菌感染率9.8% ,上呼吸道感染 3次以上发生率 18.5 %。
The treatment group of 96 cases, using Yishen Pingxiao oral solution combined with beclometasone aerosol treatment, the control group of 92 patients treated with beclomethasone aerosol. Results: The clinical cure rate in the treatment group was 50.0%, which was significantly higher than that in the control group (P <0.01). The total effective rate in the treatment group was 97.9%, which was significantly higher than that in the control group Of 83.7% (P <0.05). The long-term clinical cure rate in the treatment group was 79.2%, which was significantly higher than that in the control group (25.0%, P0.01). The long-term total effective rate in the treatment group was 99.0%, significantly higher than that in the control group (79.3% (P <0. 05). The treatment group showed no significant adverse reactions, while the control group oral fungal infection rate of 9.8%, upper respiratory tract infection more than 3 times the incidence of 18.5%.